Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Merck & Company (MRK)

Merck & Company (MRK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 204,699,232
  • Shares Outstanding, K 2,511,031
  • Annual Sales, $ 64,168 M
  • Annual Income, $ 17,117 M
  • EBIT $ 20,398 M
  • EBITDA $ 24,897 M
  • 60-Month Beta 0.39
  • Price/Sales 3.23
  • Price/Cash Flow 8.71
  • Price/Book 4.29

Options Overview Details

View History
  • Implied Volatility 34.91% ( +0.22%)
  • Historical Volatility 23.55%
  • IV Percentile 83%
  • IV Rank 48.78%
  • IV High 53.48% on 04/10/25
  • IV Low 17.23% on 09/23/24
  • Put/Call Vol Ratio 0.22
  • Today's Volume 12,616
  • Volume Avg (30-Day) 35,701
  • Put/Call OI Ratio 0.82
  • Today's Open Interest 766,423
  • Open Int (30-Day) 722,795

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 24 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate 2.01
  • Number of Estimates 7
  • High Estimate 2.13
  • Low Estimate 1.88
  • Prior Year 2.28
  • Growth Rate Est. (year over year) -11.84%

Price Performance

See More
Period Period Low Period High Performance
1-Month
78.14 +3.71%
on 06/27/25
85.00 -4.67%
on 07/10/25
+1.74 (+2.19%)
since 06/18/25
3-Month
73.31 +10.53%
on 05/15/25
85.83 -5.59%
on 04/30/25
+3.03 (+3.88%)
since 04/17/25
52-Week
73.31 +10.53%
on 05/15/25
128.73 -37.05%
on 07/26/24
-43.22 (-34.78%)
since 07/18/24

Most Recent Stories

More News
Will Increased Expenses Affect Bristol Myers' Performance?

Last month, Bristol Myers Squibb BMY announced a strategic collaboration agreement with BioNTech BNTX for the global co-development and co-commercialization of the latter’s investigational bispecific...

MRK : 80.69 (-1.02%)
PFE : 24.51 (-0.28%)
BMY : 47.60 (-0.96%)
BNTX : 109.68 (-1.22%)
How Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?

AbbVie ABBV has been expanding its oncology portfolio over the past few years. While the company was originally focused on two blood-cancer drugs — Imbruvica and Venclexta — it has since built a broader...

AZN : 69.16 (-0.14%)
MRK : 80.69 (-1.02%)
ABBV : 189.66 (-0.91%)
PFE : 24.51 (-0.28%)
This Blue-Chip Stock Is 20% Off Its Highs. Should You Buy the Dip?

Shares are down in the year to date and 20% off their 52-week high, but analysts see 30% upside ahead for Pfizer.

MRK : 80.69 (-1.02%)
PFE : 24.51 (-0.28%)
Stocks Fade as Expectations are Trimmed for Fed Rate Cut in September

The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed down -0.40%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.98%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.13%. September...

MSTR : 430.41 (-4.64%)
BLK : 1,118.02 (+1.14%)
AAPL : 211.03 (+0.48%)
JPM : 291.80 (+0.66%)
MRK : 80.69 (-1.02%)
$IUXX : 23,072.28 (-0.02%)
UNH : 283.81 (-1.48%)
COIN : 425.10 (+3.49%)
ZNU25 : 110-270 (+0.30%)
TSLA : 328.54 (+2.86%)
ESU25 : 6,339.75 (-0.01%)
AMD : 158.72 (-1.05%)
Stocks Mixed as T-Note Yields Rise

The S&P 500 Index ($SPX ) (SPY ) is unchanged, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.55%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.51%. September E-mini S&P futures (ESU25...

MSTR : 430.41 (-4.64%)
BLK : 1,118.02 (+1.14%)
AAPL : 211.03 (+0.48%)
JPM : 291.80 (+0.66%)
MRK : 80.69 (-1.02%)
$IUXX : 23,072.28 (-0.02%)
COIN : 425.10 (+3.49%)
ZNU25 : 110-270 (+0.30%)
TSLA : 328.54 (+2.86%)
ESU25 : 6,339.75 (-0.01%)
AMD : 158.72 (-1.05%)
$DOWI : 44,337.50 (-0.33%)
How Will Pfizer's Oncology Drugs Perform in Q2 Earnings?

Pfizer PFE is one of the biggest players in the oncology space — a position it strengthened with the 2023 acquisition of Seagen. The deal added four antibody-drug conjugates (ADC) — Adcetris, Padcev,...

AZN : 69.16 (-0.14%)
MRK : 80.69 (-1.02%)
PFE : 24.51 (-0.28%)
Stocks Settle Higher on Tech Stock Strength and Lower Bond Yields

The S&P 500 Index ($SPX ) (SPY ) Wednesday closed up +0.61%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.49%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.72%. September E-mini...

MSTR : 430.41 (-4.64%)
GOOGL : 185.31 (+0.94%)
AAPL : 211.03 (+0.48%)
BE : 24.86 (+2.26%)
DHI : 131.51 (-0.11%)
MRK : 80.69 (-1.02%)
VRNA : 104.95 (+0.16%)
$IUXX : 23,072.28 (-0.02%)
COIN : 425.10 (+3.49%)
UNH : 283.81 (-1.48%)
FICO : 1,540.44 (+0.99%)
ZNU25 : 110-270 (+0.30%)
Stocks Climb on Strength in the Magnificent Seven Stocks

The S&P 500 Index ($SPX ) (SPY ) today is up +0.25%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.19%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.28%. September E-mini S&P futures (ESU25...

GOOGL : 185.31 (+0.94%)
BE : 24.86 (+2.26%)
MRK : 80.69 (-1.02%)
VRNA : 104.95 (+0.16%)
WYNN : 107.60 (-1.68%)
$IUXX : 23,072.28 (-0.02%)
UNH : 283.81 (-1.48%)
ZNU25 : 110-270 (+0.30%)
MSFT : 509.45 (-0.44%)
ESU25 : 6,339.75 (-0.01%)
SBUX : 93.91 (+0.77%)
$DOWI : 44,337.50 (-0.33%)
What You Need To Know Ahead of Merck's Earnings Release

Merck is set to announce its second-quarter results later this month, and analysts anticipate double-digit earnings dip.

XLV : 132.36 (-0.27%)
$SPX : 6,297.18 (unch)
MRK : 80.69 (-1.02%)
Merck Faces Multiple Challenges: Will It Steer Through Successfully?

Merck MRK is expected to face several hurdles over the next few years that could affect its long-term growth trajectory, starting with the anticipated loss of exclusivity of its blockbuster PD-L1 inhibitor,...

JNJ : 164.37 (+0.85%)
MRK : 80.69 (-1.02%)
LLY : 770.97 (+1.24%)
PFE : 24.51 (-0.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda,...

See More

Key Turning Points

3rd Resistance Point 83.67
2nd Resistance Point 83.16
1st Resistance Point 82.34
Last Price 80.69
1st Support Level 81.02
2nd Support Level 80.51
3rd Support Level 79.69

See More

52-Week High 128.73
Fibonacci 61.8% 107.56
Fibonacci 50% 101.02
Fibonacci 38.2% 94.48
Last Price 80.69
52-Week Low 73.31

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar